aTyr Pharma logo

aTyr PharmaNASDAQ: ATYR

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$244.07 M
-3%vs. 3y high
55%vs. sector
-vs. 3y high
-vs. sector
-3%vs. 3y high
70%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 107 min ago
$3.22-$0.13(-3.85%)

Dividend

No data over the past 3 years
$20.00 K$20.00 K

Analysts recommendations

Institutional Ownership

ATYR Latest News

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point
seekingalpha.com09 September 2024 Sentiment: POSITIVE

Topline data from phase 3 EFZO-FIT study, using efzofitimod for the treatment of patients with pulmonary sarcoidosis, expected Q3 of 2025. The 7 major pulmonary sarcoidosis markets are expected to reach a value of $53.3 billion by 2034. Topline data from the phase 2 EFZO-CONNECT study, using efzofitimod for the treatment of patients with scleroderma-related ILD, expected Q2 of 2025.

aTyr Pharma to Participate in September Investor Conferences
globenewswire.com21 August 2024 Sentiment: POSITIVE

SAN DIEGO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in several upcoming investor conferences scheduled to take place in September 2024. Details of the conferences appear below: Conference: Wells Fargo Healthcare ConferenceDate: Thursday, September 5, 2024 Location: Everett, MAFormat: 1x1 Investor Meetings Conference: H.C.

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
globenewswire.com13 August 2024 Sentiment: POSITIVE

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis enrollment completed with 268 patients; topline data from this 52-week study expected in the third quarter of 2025. Ended the second quarter 2024 with $81.4 million in cash, cash equivalents, restricted cash and investments.

What type of business is aTyr Pharma?

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

What sector is aTyr Pharma in?

aTyr Pharma is in the Healthcare sector

What industry is aTyr Pharma in?

aTyr Pharma is in the Biotechnology industry

What country is aTyr Pharma from?

aTyr Pharma is headquartered in United States

What is aTyr Pharma website?

https://www.atyrpharma.com

Is aTyr Pharma in the S&P 500?

No, aTyr Pharma is not included in the S&P 500 index

Is aTyr Pharma in the NASDAQ 100?

No, aTyr Pharma is not included in the NASDAQ 100 index

Is aTyr Pharma in the Dow Jones?

No, aTyr Pharma is not included in the Dow Jones index

When was aTyr Pharma the previous earnings report?

No data

When does aTyr Pharma earnings report?

The next expected earnings date for aTyr Pharma is 08 November 2024